Analysts Expect Pfizer (PFE) to Deliver a Blowout Q3

It has been a strong earnings season so far, with about 82% of the S&P 500 companies that have reported so far exceeding analysts' earnings estimates, according to FactSet.

This week promises another jam-packed earnings calendar, with blue-chip pharmaceutical firm Pfizer (PFE, $43.55) among those releasing results.